Pacira BioSciences Inc. (PCRX)
Pacira BioSciences Inc. (PCRX) Stock Price, Analysis & Data
No hay datos disponibles
| Precio de compra | 16.74 |
| Capitalización de mercado | 968.64M |
| Ingresos (TTM) | 746.16M |
| Beneficio neto (TTM) | 14.64M |
| Beta | 0.27 |
| EPS (TTM) | 0.35 |
| Ratio PER (TTM) | 69.43 |
| Adelante PE | 7.04 |
| P/B (TTM) | 1.44 |
| P/S (TTM) | 1.28 |
| Earnings Date | Nov 5, 2026 |
| Precio de venta | 29.32 |
| Volumen | 632,031 |
| Volumen medio (20D) | 555,909 |
| Abierto | 23.21 |
| Anterior Cerrar | 23.18 |
| Rango del día | 22.79 - 23.37 |
| Rango de 52 semanas | 18.80 - 27.66 |
| analista | n/a |
| Precio objetivo | n/a |
| Dividendos | n/a |
| Fecha ex dividendo | n/a |
Acerca de PCRX
Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension indicated for the management of osteoarthritis and kne...
Desempeño financiero
En 2025, los ingresos de Pacira BioSciences fueron 726.41M, un aumento de 3.63% en comparación con 700.97M del año anterior. Las ganancias fueron 7.03M, una disminución de -107.07%.
Estados financierosSorpresa de resultados
Los analistas proyectan ingresos de ... Actualizar
1 semana hace · Simply Wall St.
Pacira BioSciences (PCRX) Could Be 35% Undervalued On Phase 1 Gene Therapy ProgressWhy Pacira BioSciences Stock Is Back in Focus Pacira BioSciences (PCRX) is drawing fresh attention after publishing two year Phase 1 data for its PCRX-201 gene therapy in knee osteoarthritis, along wi...
